Rare Occurrence of Aristolochic Acid Mutational Signatures in Oro-Gastrointestinal Tract Cancers
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Whole Exome Sequencing
2.2. Neoantigen Prediction
2.3. Mutational Signatures
3. Results
3.1. Prevalence of AA Mutations in Cancers
3.2. Mutational Signatures in OGITC
3.3. Somatic Mutation Landscape of OGITC
3.4. Copy Number Landscape of OGITC
4. Discussion
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Campisi, J. Aging, cellular senescence, and cancer. Annu. Rev. Physiol. 2013, 75, 685–705. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Talaska, G.; Al-Juburi, A.; Kadlubar, F.F. Smoking related carcinogen-DNA adducts in biopsy samples of human urinary bladder: Identification of N-(Deoxyguanosin-8-Yl)-4-aminobiphenyl as a major adduct. Proc. Natl. Acad. Sci. USA 1991, 88, 5350–5354. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wiencke, J.K.; Thurston, S.W.; Kelsey, K.T.; Varkonyi, A.; Wain, J.C.; Mark, E.J.; Christiani, D.C. Early age at smoking initiation and tobacco carcinogen DNA damage in the lung. J. Natl. Cancer Inst. 1999, 91, 614–619. [Google Scholar] [CrossRef] [Green Version]
- Nakazawa, H.; English, D.; Randell, P.L.; Nakazawa, K.; Martel, N.; Armstrong, B.K.; Yamasaki, H. UV and skin cancer: Specific P53 gene mutation in normal skin as a biologically relevant exposure measurement. Proc. Natl. Acad. Sci. USA 1994, 91, 360–364. [Google Scholar] [CrossRef] [Green Version]
- Tate, J.G.; Bamford, S.; Jubb, H.C.; Sondka, Z.; Beare, D.M.; Bindal, N.; Boutselakis, H.; Cole, C.G.; Creatore, C.; Dawson, E.; et al. COSMIC: The catalogue of somatic mutations in cancer. Nucleic Acids Res. 2019, 47, D941–D947. [Google Scholar] [CrossRef] [Green Version]
- Zhang, J.; Bajari, R.; Andric, D.; Gerthoffert, F.; Lepsa, A.; Nahal-Bose, H.; Stein, L.D.; Ferretti, V. The international cancer genome consortium data portal. Nat. Biotechnol. 2019, 37, 367–369. [Google Scholar] [CrossRef]
- The Cancer Genome Atlas Program—TCGA Research Network. Available online: https://www.cancer.gov/tcga (accessed on 10 March 2021).
- Alexandrov, L.B.; Kim, J.; Haradhvala, N.J.; Huang, M.N.; Ng, A.W.T.; Wu, Y.; Boot, A.; Covington, K.R.; Gordenin, D.A.; Bergstrom, E.N.; et al. The repertoire of mutational signatures in human cancer. Nature 2020, 578, 94–101. [Google Scholar] [CrossRef] [Green Version]
- Davies, H.; Glodzik, D.; Morganella, S.; Yates, L.R.; Staaf, J.; Zou, X.; Ramakrishna, M.; Martin, S.; Boyault, S.; Sieuwerts, A.M. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat. Med. 2017, 23, 517. [Google Scholar] [CrossRef]
- Drost, J.; Van Boxtel, R.; Blokzijl, F.; Mizutani, T.; Sasaki, N.; Sasselli, V.; de Ligt, J.; Behjati, S.; Grolleman, J.E.; van Wezel, T. Use of CRISPR-modified human stem cell organoids to study the origin of mutational signatures in cancer. Science 2017, 358, 234–238. [Google Scholar] [CrossRef] [Green Version]
- Fong, P.C.; Boss, D.S.; Yap, T.A.; Tutt, A.; Wu, P.; Mergui-Roelvink, M.; Mortimer, P.; Swaisland, H.; Lau, A.; O’Connor, M.J. Inhibition of Poly (ADP-Ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 2009, 361, 123–134. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kanjanapan, Y.; Lheureux, S.; Oza, A.M. Niraparib for the treatment of ovarian cancer. Expert Opin. Pharmacother. 2017, 18, 631–640. [Google Scholar] [CrossRef] [PubMed]
- Telli, M.L.; Timms, K.M.; Reid, J.; Hennessy, B.; Mills, G.B.; Jensen, K.C.; Szallasi, Z.; Barry, W.T.; Winer, E.P.; Tung, N.M. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin. Cancer Res. 2016, 22, 3764–3773. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mei, N.; Arlt, V.M.; Phillips, D.H.; Heflich, R.H.; Chen, T. DNA adduct formation and mutation induction by aristolochic acid in rat kidney and liver. Mutat. Res. Mol. Mech. Mutagen. 2006, 602, 83–91. [Google Scholar] [CrossRef]
- Mix, D.B.; Guinaudeau, H.; Shamma, M. The aristolochic acids and aristolactams. J. Nat. Prod. 1982, 45, 657–666. [Google Scholar] [CrossRef]
- Pfau, W.; Schmeiser, H.H.; Wiessler, M. Aristolochic acid binds covalently to the exocyclic amino group of purine nucleotides in DNA. Carcinogenesis 1990, 11, 313–319. [Google Scholar] [CrossRef]
- Chen, Y.-Y.; Chung, J.-G.; Wu, H.-C.; Bau, D.-T.; Wu, K.-Y.; Kao, S.-T.; Hsiang, C.-Y.; Ho, T.-Y.; Chiang, S.-Y. Aristolochic acid suppresses DNA repair and triggers oxidative DNA damage in human kidney proximal tubular cells. Oncol. Rep. 2010, 24, 141–153. [Google Scholar]
- Chan, J.Y.; Lim, A.H.; Boot, A.; Lee, E.; Ng, C.C.-Y.; Lee, J.Y.; Rajasegaran, V.; Liu, W.; Goh, S.; Hong, J.H.; et al. Whole exome sequencing identifies clinically relevant mutational signatures in resected hepatocellular carcinoma. Liver Cancer Int. 2020, 1, 25–35. [Google Scholar] [CrossRef]
- Ng, A.W.; Poon, S.L.; Huang, M.N.; Lim, J.Q.; Boot, A.; Yu, W.; Suzuki, Y.; Thangaraju, S.; Ng, C.C.; Tan, P. Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and throughout Asia. Sci. Transl. Med. 2017, 9, eaan6446. [Google Scholar] [CrossRef] [Green Version]
- Poon, S.L.; Huang, M.N.; Choo, Y.; McPherson, J.R.; Yu, W.; Heng, H.L.; Gan, A.; Myint, S.S.; Siew, E.Y.; Ler, L.D.; et al. Mutation signatures implicate aristolochic acid in bladder cancer development. Genome Med. 2015, 7, 38. [Google Scholar] [CrossRef] [Green Version]
- Hoang, M.L.; Chen, C.-H.; Chen, P.-C.; Roberts, N.J.; Dickman, K.G.; Yun, B.H.; Turesky, R.J.; Pu, Y.-S.; Vogelstein, B.; Papadopoulos, N.; et al. Aristolochic acid in the etiology of renal cell carcinoma. Cancer Epidemiol. Biomark. Prev. Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol. 2016, 25, 1600–1608. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Poon, S.L.; Pang, S.-T.; McPherson, J.R.; Yu, W.; Huang, K.K.; Guan, P.; Weng, W.-H.; Siew, E.Y.; Liu, Y.; Heng, H.L.; et al. Genome-wide mutational signatures of aristolochic acid and its application as a screening tool. Sci. Transl. Med. 2013, 5, 197ra101. [Google Scholar] [CrossRef] [PubMed]
- Lu, H.; Liang, Y.; Guan, B.; Shi, Y.; Gong, Y.; Li, J.; Kong, W.; Liu, J.; Fang, D.; Liu, L.; et al. Aristolochic acid mutational signature defines the low-risk subtype in upper tract urothelial carcinoma. Theranostics 2020, 10, 4323–4333. [Google Scholar] [CrossRef] [PubMed]
- Hoang, M.L.; Chen, C.-H.; Sidorenko, V.S.; He, J.; Dickman, K.G.; Yun, B.H.; Moriya, M.; Niknafs, N.; Douville, C.; Karchin, R.; et al. Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing. Sci. Transl. Med. 2013, 5, ra102–ra197. [Google Scholar] [CrossRef] [Green Version]
- Hsieh, S.-C.; Lin, I.-H.; Tseng, W.-L.; Lee, C.-H.; Wang, J.-D. Prescription profile of potentially aristolochic acid containing chinese herbal products: An analysis of national health insurance data in Taiwan between 1997 and 2003. Chin. Med. 2008, 3, 13. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cosyns, J.-P. Aristolochic acid and ‘Chinese herbs nephropathy. Drug Saf. 2003, 26, 33–48. [Google Scholar] [CrossRef]
- Arlt, V.M.; Stiborova, M.; Schmeiser, H.H. Aristolochic acid as a probable human cancer hazard in herbal remedies: A review. Mutagenesis 2002, 17, 265–277. [Google Scholar] [CrossRef] [Green Version]
- Debelle, F.D.; Vanherweghem, J.-L.; Nortier, J.L. Aristolochic acid nephropathy: A worldwide problem. Kidney Int. 2008, 74, 158–169. [Google Scholar] [CrossRef] [Green Version]
- Jusakul, A.; Cutcutache, I.; Yong, C.H.; Lim, J.Q.; Huang, M.N.; Padmanabhan, N.; Nellore, V.; Kongpetch, S.; Ng, A.W.T.; Ng, L.M.; et al. Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov. 2017, 7, 1116–1135. [Google Scholar] [CrossRef] [Green Version]
- Li, R.; Du, Y.; Chen, Z.; Xu, D.; Lin, T.; Jin, S.; Wang, G.; Liu, Z.; Lu, M.; Chen, X.; et al. Macroscopic somatic clonal expansion in morphologically normal human urothelium. Science 2020, 370, 82–89. [Google Scholar] [CrossRef]
- Li, H.; Durbin, R. Fast and accurate long-read alignment with burrows–Wheeler transform. Bioinformatics 2010, 26, 589–595. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Van der Auwera, G.A.; Carneiro, M.O.; Hartl, C.; Poplin, R.; del Angel, G.; Levy-Moonshine, A.; Jordan, T.; Shakir, K.; Roazen, D.; Thibault, J.; et al. From FastQ data to high-confidence variant calls: The genome analysis toolkit best practices pipeline. Curr. Protoc. Bioinforma. 2013, 43, 11.10.1–11.10.33. [Google Scholar] [CrossRef]
- McLaren, W.; Gil, L.; Hunt, S.E.; Riat, H.S.; Ritchie, G.R.; Thormann, A.; Flicek, P.; Cunningham, F. The ensembl variant effect predictor. Genome Biol. 2016, 17, 122. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kandoth, C.; Gao, J.; qwangmsk; Mattioni, M.; Struck, A.; Boursin, Y.; Penson, A.; Chavan, S. Mskcc/Vcf2maf: Vcf2maf v1.6.16; Zenodo: Geneva, Switzerland, 2018. [Google Scholar]
- Crowdis, J.; He, M.X.; Reardon, B.; Van Allen, E.M. CoMut: Visualizing integrated molecular information with comutation plots. Bioinformatics 2020, 36, 4348–4349. [Google Scholar] [CrossRef] [PubMed]
- Talevich, E.; Shain, A.H.; Botton, T.; Bastian, B.C. CNVkit: Genome-wide copy number detection and visualization from targeted DNA sequencing. PLoS Comput. Biol. 2016, 12, e1004873. [Google Scholar] [CrossRef]
- Niu, B.; Ye, K.; Zhang, Q.; Lu, C.; Xie, M.; McLellan, M.D.; Wendl, M.C.; Ding, L. MSIsensor: Microsatellite instability detection using paired tumor-normal sequence data. Bioinformatics 2014, 30, 1015–1016. [Google Scholar] [CrossRef] [Green Version]
- NeoPredPipe: High-Throughput Neoantigen Prediction and Recognition Potential Pipeline|BMC Bioinformatics|Full Text. Available online: https://bmcbioinformatics.biomedcentral.com/articles/10.1186/s12859-019-2876-4 (accessed on 16 February 2021).
- Wang, K.; Li, M.; Hakonarson, H. ANNOVAR: Functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010, 38, e164. [Google Scholar] [CrossRef]
- Jurtz, V.; Paul, S.; Andreatta, M.; Marcatili, P.; Peters, B.; Nielsen, M. NetMHCpan-4.0: Improved peptide–MHC class i interaction predictions integrating eluted ligand and peptide binding affinity data. J. Immunol. 2017, 199, 3360–3368. [Google Scholar] [CrossRef]
- Chen, T.-W.; Lee, C.-C.; Liu, H.; Wu, C.-S.; Pickering, C.R.; Huang, P.-J.; Wang, J.; Chang, I.Y.-F.; Yeh, Y.-M.; Chen, C.-D.; et al. APOBEC3A Is an oral cancer prognostic biomarker in taiwanese carriers of an APOBEC Deletion Polymorphism. Nat. Commun. 2017, 8, 1–13. [Google Scholar] [CrossRef]
- Mermel, C.H.; Schumacher, S.E.; Hill, B.; Meyerson, M.L.; Beroukhim, R.; Getz, G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011, 12, R41. [Google Scholar] [CrossRef] [Green Version]
- Chen, C.-H.; Dickman, K.G.; Moriya, M.; Zavadil, J.; Sidorenko, V.S.; Edwards, K.L.; Gnatenko, D.V.; Wu, L.; Turesky, R.J.; Wu, X.-R.; et al. Aristolochic acid-associated urothelial cancer in Taiwan. Proc. Natl. Acad. Sci. USA 2012, 109, 8241–8246. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jelaković, B.; Karanović, S.; Vuković-Lela, I.; Miller, F.; Edwards, K.L.; Nikolić, J.; Tomić, K.; Slade, N.; Brdar, B.; Turesky, R.J.; et al. Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid. Kidney Int. 2012, 81, 559–567. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schmeiser, H.H.; Bieler, C.A.; Wiessler, M.; van Ypersele de Strihou, C.; Cosyns, J.-P. Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with chinese herbs nephropathy. Cancer Res. 1996, 56, 2025–2028. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nortier, J.L.; Martinez, M.-C.M.; Schmeiser, H.H.; Arlt, V.M.; Bieler, C.A.; Petein, M.; Depierreux, M.F.; De Pauw, L.; Abramowicz, D.; Vereerstraeten, P.; et al. Urothelial Carcinoma associated with the Use of a Chinese Herb (Aristolochia Fangchi). Available online: https://www.nejm.org/doi/10.1056/NEJM200006083422301 (accessed on 15 April 2021).
- Sidorenko, V.S.; Attaluri, S.; Zaitseva, I.; Iden, C.R.; Dickman, K.G.; Johnson, F.; Grollman, A.P. Bioactivation of the human carcinogen aristolochic acid. Carcinogenesis 2014, 35, 1814–1822. [Google Scholar] [CrossRef] [Green Version]
- Xiao, Y.; Ge, M.; Xue, X.; Wang, C.; Wang, H.; Wu, X.; Li, L.; Liu, L.; Qi, X.; Zhang, Y.; et al. Hepatic cytochrome P450s metabolize aristolochic acid and reduce its kidney toxicity. Kidney Int. 2008, 73, 1231–1239. [Google Scholar] [CrossRef] [Green Version]
- Stiborová, M.; Frei, E.; Breuer, A.; Wiessler, M.; Schmeiser, H.H. Evidence for reductive activation of carcinogenic aristolochic acids by prostaglandin H synthase-(32)P-Postlabeling analysis of DNA adduct formation. Mutat. Res. 2001, 493, 149–160. [Google Scholar] [CrossRef]
- Stiborova, M.; Mares, J.; Levova, K.; Pavlickova, J.; Barta, F.; Hodek, P.; Frei, E.; Schmeiser, H.H. Role of cytochromes P450 in metabolism of carcinogenic aristolochic acid I: Evidence of their contribution to aristolochic acid I detoxication and activation in rat liver. Neuro Endocrinol. Lett. 2011, 32 (Suppl. 1), 121–130. [Google Scholar]
- Chang, S.-Y.; Weber, E.J.; Sidorenko, V.S.; Chapron, A.; Yeung, C.K.; Gao, C.; Mao, Q.; Shen, D.; Wang, J.; Rosenquist, T.A.; et al. Human liver-kidney model elucidates the mechanisms of aristolochic acid nephrotoxicity. JCI Insight 2017, 2, e95978. [Google Scholar] [CrossRef]
- Lu, Z.-N.; Luo, Q.; Zhao, L.-N.; Shi, Y.; Wang, N.; Wang, L.; Han, Z.-G. The mutational features of aristolochic acid–induced mouse and human liver cancers. Hepatology 2020, 71, 929–942. [Google Scholar] [CrossRef]
- Gao, Q.; Zhu, H.; Dong, L.; Shi, W.; Chen, R.; Song, Z.; Huang, C.; Li, J.; Dong, X.; Zhou, Y.; et al. Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma. Cell 2019, 179, 561–577.e22. [Google Scholar] [CrossRef]
- Jiang, T.; Shi, T.; Zhang, H.; Hu, J.; Song, Y.; Wei, J.; Ren, S.; Zhou, C. Tumor neoantigens: From basic research to clinical applications. J. Hematol. Oncol. J. Hematol. Oncol. 2019, 12, 93. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mattos-Arruda, L.D.; Vazquez, M.; Finotello, F.; Lepore, R.; Porta, E.; Hundal, J.; Amengual-Rigo, P.; Ng, C.K.Y.; Valencia, A.; Carrillo, J.; et al. Neoantigen prediction and computational perspectives towards clinical benefit: Recommendations from the ESMO precision medicine working group. Ann. Oncol. 2020, 31, 978–990. [Google Scholar] [CrossRef] [PubMed]
- Matsushita, H.; Hasegawa, K.; Oda, K.; Yamamoto, S.; Asada, K.; Karasaki, T.; Yabuno, A.; Nishijima, A.; Nejo, T.; Kobayashi, Y.; et al. Neoantigen load and HLA-Class I expression identify a subgroup of tumors with a T-cell-inflamed phenotype and favorable prognosis in homologous recombination-proficient high-grade serous ovarian carcinoma. J. Immunother. Cancer 2020, 8, e000375. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Lim, A.H.; Chan, J.Y.; Yu, M.-C.; Wu, T.-H.; Hong, J.H.; Ng, C.C.Y.; Low, Z.J.; Liu, W.; Vikneswari, R.; Sung, P.-C.; et al. Rare Occurrence of Aristolochic Acid Mutational Signatures in Oro-Gastrointestinal Tract Cancers. Cancers 2022, 14, 576. https://doi.org/10.3390/cancers14030576
Lim AH, Chan JY, Yu M-C, Wu T-H, Hong JH, Ng CCY, Low ZJ, Liu W, Vikneswari R, Sung P-C, et al. Rare Occurrence of Aristolochic Acid Mutational Signatures in Oro-Gastrointestinal Tract Cancers. Cancers. 2022; 14(3):576. https://doi.org/10.3390/cancers14030576
Chicago/Turabian StyleLim, Abner Herbert, Jason Yongsheng Chan, Ming-Chin Yu, Tsung-Han Wu, Jing Han Hong, Cedric Chuan Young Ng, Zhen Jie Low, Wei Liu, Rajasegaran Vikneswari, Pin-Cheng Sung, and et al. 2022. "Rare Occurrence of Aristolochic Acid Mutational Signatures in Oro-Gastrointestinal Tract Cancers" Cancers 14, no. 3: 576. https://doi.org/10.3390/cancers14030576